Authors: | Wen, P. Y.; Schiff, D.; Cloughesy, T. F.; Reardon, D. A.; Batchelor, T. T.; Chabner, B. A.; Flaherty, K.; De Groot, J. F.; Gilbert, M. R.; Galanis, E.; Chang, S. M.; Schwartz, G. K.; Peereboom, D.; Mehta, M. P.; Yung, W. K. A.; Grossman, S. A.; Prados, M. D.; Deangelis, L. M. |
Article Title: | It is time to include patients with brain tumors in phase I trials in oncology |
Keywords: | cancer survival; drug activity; bevacizumab; drug penetration; note; drug targeting; cancer patient; rituximab; temozolomide; neurotoxicity; brain tumor; drug structure; etiracetam; topiramate; glioblastoma; blood brain barrier; drug metabolism; maximum tolerated dose; corticosteroid; life expectancy; molecular weight; lipophilicity; phenytoin; carbamazepine; harkoseride; lamotrigine; pregabalin; phase 1 clinical trial (topic) |
Journal Title: | Journal of Clinical Oncology |
Volume: | 29 |
Issue: | 24 |
ISSN: | 0732-183X |
Publisher: | American Society of Clinical Oncology |
Date Published: | 2011-08-20 |
Start Page: | 3211 |
End Page: | 3213 |
Language: | English |
DOI: | 10.1200/jco.2011.36.6328 |
PROVIDER: | scopus |
PUBMED: | 21768451 |
PMCID: | PMC4836609 |
DOI/URL: | |
Notes: | --- - "Export Date: 3 October 2011" - "CODEN: JCOND" - "Source: Scopus" |